Announcement

Collapse
No announcement yet.

Mol Biotechnol . Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Mol Biotechnol . Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19


    Mol Biotechnol


    . 2021 Feb 24.
    doi: 10.1007/s12033-021-00303-0. Online ahead of print.
    Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19


    Seyed Mehdi Sadat 1 , Mohammad Reza Aghadadeghi 2 , Masoume Yousefi 1 , Arezoo Khodaei 1 , Mona Sadat Larijani 1 , Golnaz Bahramali 3



    Affiliations

    Abstract

    The emerging Coronavirus Disease 2019 (COVID-19) pandemic has posed a serious threat to the public health worldwide, demanding urgent vaccine provide. According to the virus feature as an RNA virus, a high rate of mutations imposes some vaccine design difficulties. Bioinformatics tools have been widely used to make advantage of conserved regions as well as immunogenicity. In this study, we aimed at immunoinformatic evaluation of SARS-CoV-2 proteins conservancy and immunogenicity to design a preventive vaccine candidate. Spike, Membrane and Nucleocapsid amino acid sequences were obtained, and four possible fusion proteins were assessed and compared in terms of structural features and immunogenicity, and population coverage. MHC-I and MHC-II T-cell epitopes, the linear and conformational B-cell epitopes were evaluated. Among the predicted models, the truncated form of Spike in fusion with M and N protein applying AAY linker has high rate of MHC-I and MCH-II epitopes with high antigenicity and acceptable population coverage of 82.95% in Iran and 92.51% in Europe. The in silico study provided truncated Spike-M-N SARS-CoV-2 as a potential preventive vaccine candidate for further in vivo evaluation.

    Keywords: COVID-19; In silico; Protein; SARS-CoV-2; Vaccine design.

Working...
X